

AERSMine-facilitated normalizations and ontological aggregations: diuretics			
	FDA - 'as is'	AERSMine - normalized	% gain
diuretic	64,293	363,889	466
thiazide	64,293	137,854	114
bendroflumethiazide	5,131	9,195	79
hydroflumethiazide	6	39	550
hydrochlorothiazide	57,833	125,573	117
chlorothiazide	348	532	53
polythiazide	0	10	inf
trichlormethiazide	951	2,367	149
cyclopenthiazide	11	14	27
methylclothiazide	11	30	173
cyclothiazide	0	1	inf

*un-normalized (top term aggregation-based for Un-normalized FAERS). Prior to normalizations, a database search would retrieve the following number of patient reports

AERSMine normalized counts - aggregating brand names, foreign names, spelling variants, correction for typographical errors, drug salts - hcl, sulfate, citrate etc.

AERSMine-facilitated normalizations and ontological aggregations: agents acting on the renin-angiotensin system			
	FDA - 'as is'	AERSMine - normalized	% gain
agents acting on the renin angiotensin system*	167,680	519,599	210
ace inhibitors, plain*	167,680	291,927	74
captopril	7,464	8,889	19
enalapril	9,713	41,182	324
lisinopril	104,176	124,621	20
perindopril	4,099	17,153	318
ramipril	35,816	57,377	60
quinapril	2,817	11,856	321
benazepril	1,463	18,937	1194
cilazapril	484	920	90
fosinopril	524	6,155	1075
trandolapril	902	4,560	406
spirapril	11	32	191
delapril	5	94	1780
moexipril	41	883	2054
temocapril	22	826	3655
zofenopril	84	157	87
imidapril	59	1,604	2619